Drug intelligence / Profile preview

LY4006896

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

LY4006896 is an investigational drug developed by Eli Lilly for the treatment of Parkinson's disease. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and individuals with Parkinson's disease. The drug is administered intravenously (IV). As of now, the specific mechanism of action and molecular target have not been publicly disclosed. The primary focus of ongoing studies is to generate evidence regarding its effects compared to placebo in relevant populations[2][3][5][6][7].

Beyond the preview

Go deeper on LY4006896.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4006896.

Explore the full profile